Addex Therapeutics (ADXN) Projected to Post Quarterly Earnings on Monday

Addex Therapeutics (NASDAQ:ADXN) is expected to issue its quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($1.42) per share for the quarter.

Addex Therapeutics Trading Up 0.8%

Shares of NASDAQ:ADXN opened at $8.28 on Monday. The stock has a market capitalization of $8.77 million, a P/E ratio of -24.34 and a beta of 1.62. Addex Therapeutics has a 1-year low of $6.51 and a 1-year high of $13.27. The business has a 50-day moving average price of $7.62 and a two-hundred day moving average price of $7.80.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.